Not cross promoting here Steini. You've for some time compared CHM to ALA and just so your readers get both sides of the story here's my 2-bobs.
Recent commentary on the ALA share price has the intrinsic value around 19 cps, so it could be currently undervalued.
One of the reasons that it is holding up quite well is that it is not in the highly competitive areas of CAR-T or CAR-NK.
Another is all of it's focus is allogeneic vs autologous therapies, the benefits of the former are well stated.
Another is that as another micro-cap (all of which have no money) it's pipeline is laser focused and not shotgun focused.
You've mentioned a couple of times that there is no IND for the prime drug candidate. There's 2 reasons. Firstly the Ph1 trials may not be happen in the US and it could be that the trials will be held here under TGA approval, the ALA Chair has a predisposition for that.
If they are to be held in the US, the IND requires 3 things; animal tox studies, trial protocol and manufacturing data. They announced manufacturing completion just this week - so you know.
But you know the best thing about ALA?
Hopper's not there.
CHM Price at posting:
1.7¢ Sentiment: None Disclosure: Not Held
(20min delay)